K Vanden Houte
Overview
Explore the profile of K Vanden Houte including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
123
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hottat N, Van Pachterbeke C, Vanden Houte K, Denolin V, Jani J, Cannie M
Ultrasound Obstet Gynecol
. 2020 May;
57(3):478-487.
PMID: 32438461
Objectives: To validate prospectively the ADNEX magnetic resonance (MR) scoring system to assess adnexal masses and to evaluate a new, modified ADNEX MR scoring system that incorporates diffusion-weighted imaging (DWI)...
2.
Kadi R, Massard V, Vanden Houte K, Gerard C, Divano L, Jani J, et al.
JBR-BTR
. 2015 Jan;
97(4):262.
PMID: 25603640
No abstract available.
3.
Mesquita M, Fosso C, Bakoto Sol E, Libertalis M, Corazza F, Vanden Houte K, et al.
Acta Clin Belg
. 2011 Jun;
66(2):104-9.
PMID: 21630606
Renal biopsy is the definitive diagnostic test in patients with renal parenchymal disease. Renal biopsy registry is an important tool which can provide valuable data concerning early and correct epidemiological...
4.
Van Pachterbeke C, Bucella D, Rozenberg S, Manigart Y, Gilles C, Larsimont D, et al.
Gynecol Oncol
. 2009 Aug;
115(1):69-74.
PMID: 19647859
Objective: Randomized controlled trial evaluating a topical treatment for cervical intraepithelial neoplasia 2 and 3 (CIN 2+) using cidofovir. Methods: Fifty-three women with a biopsy-proven CIN 2+ were randomly assigned,...
5.
Baeyens L, Amat S, Vanden Houte K, Vanhoutte P, LHermite M
Eur J Gynaecol Oncol
. 2008 Dec;
29(5):535-7.
PMID: 19051830
Unlabelled: Small cell ovarian tumors are rare and highly malignant, occurring mainly in young patients. Early mortality is high due to the lack of an effective treatment. The first adjuvant...
6.
Dieriks B, Hoorens A, Vanden Houte K, Verbeelen D
Nephrol Dial Transplant
. 2006 May;
21(7):2027.
PMID: 16687432
No abstract available.
7.
Deman A, Vanden Houte K, Verbeelen D
Clin Nephrol
. 2004 May;
61(4):275-7.
PMID: 15125033
The present case describes the unusual association of a crescentic glomerulonephritis (GN), diabetes mellitus and a monoclonal gammopathy. After an unexplained deterioration of renal function, a kidney biopsy was performed....
8.
Van den Branden C, Ceyssens B, De Craemer D, Pauwels M, Vanden Houte K, De Bleser P, et al.
Nephron
. 2000 Oct;
86(2):167-75.
PMID: 11014987
Excessive generation of reactive oxygen intermediates can induce changes in the cellular antioxidant defence system. In this study we examine the antioxidant enzyme status and the expression of fibrosis-related marker...
9.
Verbeelen D, De Craemer D, Peeters P, Vanden Houte K, Van den Branden C
Nephron
. 1998 Sep;
80(2):214-9.
PMID: 9736823
In rats with five-sixths nephrectomy (remnant kidney), blood pressure, glomerulosclerosis, and proteinuria are significantly reduced by administration of the angiotensin-converting enzyme inhibitor enalapril, during 16 weeks after reduction of the...
10.
Van den Branden C, Gabriels M, Vamecq J, Vanden Houte K, Verbeelen D
Nephron
. 1997 Jan;
77(3):319-24.
PMID: 9375827
Nephron loss leads to increased production of reactive oxygen intermediates. We measured the effect of carvedilol, a beta-blocking drug with radical scavenging properties, on renal function, glomerulosclerosis, antioxidant enzyme status...